This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen de acción SURF
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de Surface Oncology, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.07 |
| 52 Week High | US$1.43 |
| 52 Week Low | US$0.56 |
| Beta | 1.75 |
| 1 Month Change | 11.47% |
| 3 Month Change | 38.96% |
| 1 Year Change | -21.90% |
| 3 Year Change | -83.79% |
| 5 Year Change | -89.91% |
| Change since IPO | -91.97% |
Noticias y actualizaciones recientes
Recent updates
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically
Nov 07
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts
Aug 08Surface Oncology GAAP EPS of -$0.46 misses by $0.01
Aug 03Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
May 25News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
May 11Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 23Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Jan 18Is Surface Oncology (NASDAQ:SURF) A Risky Investment?
Nov 11Surface Oncology: Staying The Course
Oct 24Surface Oncology: A Diverse, But Early Pipeline
Jul 13Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
Jun 07Surface Oncology EPS beats by $0.04, beats on revenue
May 05Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like
Mar 15Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 16
Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets
Dec 09What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?
Dec 08Surface Oncology shares rise 13% on Fast Track tag for SRF388
Nov 11Rentabilidad de los accionistas
| SURF | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -0.9% | -1.5% | -0.7% |
| 1Y | -21.9% | 0.1% | 22.3% |
Rentabilidad vs. Industria: SURF underperformed the US Biotechs industry which returned 3.5% over the past year.
Rentabilidad vs. Mercado: SURF underperformed the US Market which returned 7.4% over the past year.
Volatilidad de los precios
| SURF volatility | |
|---|---|
| SURF Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: SURF's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: SURF's weekly volatility (8%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2014 | 35 | Rob Ross | www.surfaceoncology.com |
Resumen de fundamentos de Surface Oncology, Inc.
| Estadísticas fundamentales de SURF | |
|---|---|
| Capitalización bursátil | US$65.08m |
| Beneficios(TTM) | -US$92.50m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.7x
Ratio precio-beneficio (PE)¿Está SURF sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de SURF | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$67.00m |
| Beneficio bruto | -US$67.00m |
| Otros gastos | US$25.50m |
| Beneficios | -US$92.50m |
Últimos beneficios comunicados
Jun 30, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.52 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado SURF a largo plazo?
Ver rendimiento histórico y comparativa